CoChat
Sign Up
Cited by 74Eating Disorders and BehaviorsPharmacology and Obesity TreatmentNutrition, Health and Food Behavior

Pharmacological management of binge eating disorder: current and emerging treatment options

Open access
McElroy, Susan, Guerdjikova, Anna I., Mori, Nicole, O’Melia, Anne·2012·Therapeutics and Clinical Risk Management
DOI 10.2147/tcrm.s25574PMC PMC3363296
Open this paper in CoChat — free accountOpen PDF

Abstract

Growing evidence suggests that pharmacotherapy may be beneficial for some patients with binge eating disorder (BED), an eating disorder characterized by repetitive episodes of uncontrollable consumption of abnormally large amounts of food without inappropriate weight loss behaviors. In this paper, we provide a brief overview of BED and review the rationales and data supporting the effectiveness of specific medications or medication classes in treating patients with BED. We conclude by summarizing these data, discussing the role of pharmacotherapy in the BED treatment armamentarium, and suggesting future areas for research.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/tcrm.s25574

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Phentermine/topiramate ER has shown efficacy in reducing binge symptoms, often overlapping with emotional eating.

    “This combination has shown efficacy in reducing binge symptoms, often overlapping with emotional eating.”

    From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [128]

    The Antiepileptic drugs section (page unavailable) reports reduced binge frequency with topiramate alone. It describes phentermine/topiramate ER as effective for weight loss and maintenance in obesity, not for reducing binge symptoms. The passages also do not establish the claimed overlap with emotional eating. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

  • Phentermine curbs appetite while topiramate enhances inhibitory control.

    “Phentermine curbs appetite while topiramate enhances inhibitory control [128].”

    From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [128]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 205 · Cited by 74

Research works printed but not linked: 178

  1. [1]American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision Washington, DC American Psychiatric Association 2000
  2. [2]Wonderlich SA Gordon KH Mitchell JE Crosby RD Engel SG The validity and clinical utility of binge eating disorder Int J Eat Disord 2009 42 8 687 705 19621466
  3. [5]Bulik CM Reichborn-Kjennerud T Medical morbidity in binge eating disorder Int J Eat Disord 2003 34 Suppl S39 46 12900985
  4. [6]Hudson JI Lalonde JK Berry JM Binge-eating disorder as a distinct familial phenotype in obese individuals Arch Gen Psychiatry 2006 63 3 313 319 16520437
  5. [7]Hudson JI Lalonde JK Coit CE Longitudinal study of the diagnosis of components of the metabolic syndrome in individuals with binge eating disorder Am J Clin Nutr 2010 91 6 1568 1573 20427731 PMC2869508
  6. [8]Javaras KN Pope HG Lalonde JK Co-occurrence of binge eating disorder with psychiatric and medical disorders J Clin Psychiatry 2008 69 2 266 273 18348600
  7. [9]Pope HG Jr Lalonde JK Pindyck LJ Binge eating disorder: a stable syndrome Am J Psychiatry 2006 163 12 2181 2183 17151172
  8. [10]Wilson GT Treatment of binge eating disorder Psychiatr Clin North Am 2011 34 4 773 783 22098803
  9. [11]Yager J Binge eating disorder: The search for better treatments Am J Psychiatry 2008 165 1 4 6 18178748
  10. [13]Wadden TA Faulconbridge LF Jones-Corneille LR Binge eating disorder and the outcome of bariatric surgery at one year: a prospective, observational study Obesity (Silver Spring) 2011 19 6 1220 1228 21253005 PMC3085093
  11. [14]Colles SL Dixon JB O’Brien PE Grazing and loss of control related to eating: Two high-risk factors following bariatric surgery Obesity (Silver Spring) 2008 16 3 615 622 18239603
  12. [15]Kofman MD Lent MR Swencionis C Maladaptive eating patterns, quality of life, and weight outcomes following gastric bypass: Results of an Internet survey Obesity (Silver Spring) 2010 18 10 1938 1943 20168309
  13. [16]Livhits M Mercado C Yermilov I Preoperative predictors of weight loss following bariatric surgery: systematic review Obes Surg 2012 22 1 70 89 21833817
  14. [17]de Zwaan M Hilbert A Swan-Kremeier L Comprehensive interview assessment of eating behavior 18–35 months after gastric bypass surgery for morbid obesity Surg Obes Relat Dis 2010 6 1 79 85 19837012
  15. [18]Berkman ND Bulik CM Brownley KA Management of eating disorders Evid Rep Technol Assess (Full Rep) 2006 135 1 166 17628126 PMC4780981
  16. [19]Hudson JI Carter WP Pope HG Jr Antidepressant treatment of binge-eating disorder: research findings and clinical guidelines J Clin Psychiatry 1996 57 Suppl 8 73 79 8698686
  17. [20]Ramoz N Versini A Gorwood P Eating disorders: an overview of treatment responses and the potential impact of vulnerability genes and endophenotypes Expert Opin Pharmacother 2007 8 13 2029 2044 17714058
  18. [21]Reas DL Grilo CM Review and meta-analysis of pharmacotherapy for binge-eating disorder Obesity (Silver Spring) 2008 16 9 2024 2038 19186327 PMC3650491
  19. [22]Steffen KJ Roerig JL Mitchell JE Uppala S Emerging drugs for eating disorder treatment Expert Opin Emerg Drugs 2006 11 2 315 336 16634704
  20. [24]Zhu AJ Walsh BT Pharmacologic treatment of eating disorders Can J Psychiatry 2002 47 3 227 234 11987473
  21. [26]American Psychiatric Association Treatment of patients with eating disorders, third edition. American Psychiatric Association Am J Psychiatry 2006 163 Suppl 7 4 54 16925191
  22. [29]Devlin MJ Goldfein JA Dobrow I What is this thing called BED? Current status of binge eating disorder nosology Int J Eat Disord 2003 34 Suppl S2 18 12900982
  23. [30]Grilo CM Masheb RM Onset of dieting versus binge eating in outpatients with binge eating disorder Int J Obes Relat Metab Disord 2000 24 4 404 409 10805495
  24. [31]Walsh BT Boudreau G Laboratory studies of binge eating disorder Int J Eat Disord 2003 34 Suppl S30 38 12900984
  25. [32]Schienle A Schafer A Hermann A Vaitl D Binge-eating disorder: reward sensitivity and brain activation to images of food Biol Psychiatry 2009 65 8 654 661 18996508
  26. [33]Goldschmidt AB Le Grange D Powers P Eating disorder symptomatology in normal-weight vs obese individuals with binge eating disorder Obesity (Silver Spring) 2011 19 7 1515 1518 21331066 PMC3818144
  27. [34]Brandao PP Garcia-Souza EP Neves FA Leptin/adiponectin ratio in obese women with and without binge eating disorder Neuro Endocrinol Lett 2010 31 3 353 358 20588239
  28. [35]Latner JD Clyne C The diagnostic validity of the criteria for binge eating disorder Int J Eat Disord 2008 41 1 1 14 17922537
  29. [36]Mobbs O Iglesias K Golay A Van der Linden M Cognitive deficits in obese persons with and without binge eating disorder. Investigation using a mental flexibility task Appetite 2011 57 1 263 271 21600255
  30. [37]Wang GJ Geliebter A Volkow ND Enhanced striatal dopamine release during food stimulation in binge eating disorder Obesity (Silver Spring) 2011 19 8 1601 1608 21350434 PMC3144277
  31. [38]Striegel-Moore RH Franko DL Should binge eating disorder be included in the DSM-V? A critical review of the state of the evidence Annu Rev Clin Psychol 2008 4 305 324 18370619
  32. [40]Wilson GT Sysko R Frequency of binge eating episodes in bulimia nervosa and binge eating disorder: Diagnostic considerations Int J Eat Disord 2009 42 7 603 610 19610014 PMC3864806
  33. [41]Hudson JI Coit CE Lalonde JK Pope HG Jr By how much will the proposed new DSM-5 criteria increase the prevalence of binge eating disorder? Int J Eat Disord 2012 45 1 139 141 22170026
  34. [42]McElroy SL Guerdjikova A O’Melia A Mori N Keck PEJ Pharmaco-therapy of the eating disorders Agras S Oxford Handbook of Eating Disorders New York, NY Oxford University Press Inc 2010
  35. [44]Harrold JA Dovey TM Blundell JE Halford JC CNS regulation of appetite Neuropharmacology 1 30 2012 [Epub ahead of print.] 22313528
  36. [45]Berner LA Bocarsly ME Hoebel BG Avena NM Pharmacological interventions for binge eating: lessons from animal models, current treatments, and future directions Curr Pharm Des 2011 17 12 1180 1187 21492094
  37. [46]Mathes WF Brownley KA Mo X Bulik CM The biology of binge eating Appetite 2009 52 3 545 553 19501749 PMC2694569
  38. [47]Tecott LH Sun LM Akana SF Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors Nature 1995 374 6522 542 546 7700379
  39. [48]Geliebter A Yahav EK Gluck ME Hashim SA Gastric capacity, test meal intake, and appetitive hormones in binge eating disorder Physiol Behav 2004 81 5 735 740 15234178
  40. [49]Hargrave SL Kinzig KP Repeated gastric distension alters food intake and neuroendocrine profiles in rats Physiol Behav 2011 105 4 975 981 22115950 PMC3260410
  41. [50]Biton V Weight change and antiepileptic drugs: health issues and criteria for appropriate selection of an antiepileptic agent Neurologist 2006 12 3 163 167 16688018
  42. [52]Halford JC Boyland EJ Blundell JE Kirkham TC Harrold JA Pharmacological management of appetite expression in obesity Nat Rev Endocrinol 2010 6 5 255 269 20234354
  43. [53]Biton V Clinical pharmacology and mechanism of action of zonisamide Clin Neuropharmacol 2007 30 4 230 240 17762320
  44. [54]Clifton PG Kennett GA Monoamine receptors in the regulation of feeding behaviour and energy balance CNS Neurol Disord Drug Targets 2006 5 3 293 312 16787230
  45. [55]Guardia D Rolland B Karila L Cottencin O GABAergic and glutamatergic modulation in binge eating: therapeutic approach Curr Pharm Des 2011 17 14 1396 1409 21524265
  46. [56]Husum H Van Kammen D Termeer E Bolwig G Mathe A Topiramate normalizes hippocampal neuropeptide Y-LI in flinders sensitive line ‘depressed’ rats and upregulates neuropeptide Y, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects Neuropsychopharmacology 2003 28 7 1292 1299 12700690
  47. [57]Kwak SE Kim JE Kim DS Differential effects of vigabatrin and zonisamide on the neuropeptide Y system in the hippocampus of seizure prone gerbil Neuropeptides 2005 39 5 507 513 16194568
  48. [58]Meister B Neurotransmitters in key neurons of the hypothalamus that regulate feeding behavior and body weight Physiol Behav 2007 92 1–2 263 271 17586536
  49. [59]Ravussin E Smith SR Mitchell JA Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy Obesity (Silver Spring) 2009 17 9 1736 1743 19521351 PMC2754219
  50. [61]McElroy SL Hudson JI Capece JA Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study Biol Psychiatry 2007 61 9 1039 1048 17258690
  51. [62]Wilfley DE Crow SJ Hudson JI Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study Am J Psychiatry 2008 165 1 51 58 18056225
  52. [63]Aronne LJ Powell AG Apovian CM Emerging pharmacotherapy for obesity Expert Opin Emerg Drugs 2011 16 3 587 596 21834735
  53. [64]Chen Z Yang J Tobak A Designing new treatments for depression and anxiety IDrugs 2008 11 3 189 197 18311656
  54. [65]Fong TM Development of anti-obesity agents: drugs that target neuropeptide and neurotransmitter systems Expert Opin Investig Drugs 2008 17 3 321 325 18321231
  55. [66]Halford JC Boyland EJ Lawton CL Blundell JE Harrold JA Serotonergic anti-obesity agents: past experience and future prospects Drugs 2011 71 17 2247 2255 22085383
  56. [67]Johannessen Landmark C Johannessen SI Pharmacological management of epilepsy: recent advances and future prospects Drugs 2008 68 14 1925 1939 18778117
  57. [68]Machado-Vieira R Salvadore G DiazGranados N New therapeutic targets for mood disorders Scientific World Journal 2010 10 713 726 20419280 PMC3035047
  58. [69]Appolinario JC McElroy SL Pharmacological approaches in the treatment of binge eating disorder Curr Drug Targets 2004 5 3 301 307 15058314
  59. [70]Bacaltchuk J Hay P Antidepressants versus placebo for people with bulimia nervosa Cochrane Database Syst Rev 2003 4 CD003391 11687198 PMC6991155
  60. [71]Horne RL Ferguson JM Pope HG Jr Treatment of bulimia with bupropion: a multicenter controlled trial J Clin Psychiatry 1988 49 7 262 266 3134343
  61. [72]Shapiro JR Berkman ND Brownley KA Sedway JA Lohr KN Bulik CM Bulimia nervosa treatment: a systematic review of randomized controlled trials Int J Eat Disord 2007 40 4 321 336 17370288
  62. [73]Monteleone P Tortorella A Castaldo E Maj M Association of a functional serotonin transporter gene polymorphism with binge eating disorder Am J Med Genet B Neuropsychiatr Genet 2006 141B 1 7 9 16249995
  63. [74]Latagliata EC Patrono E Puglisi-Allegra S Ventura R Food seeking in spite of harmful consequences is under prefrontal cortical noradrenergic control BMC Neurosci 2010 11 15 20141625 PMC2827417
  64. [75]Alger SA Schwalberg MD Bigaouette JM Michalek AV Howard LJ Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects Am J Clin Nutr 1991 53 4 865 871 2008865
  65. [77]Grilo CM Masheb RM Wilson GT Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison Biol Psychiatry 2005 57 3 301 309 15691532
  66. [78]Guerdjikova AI McElroy SL Kotwal R High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial Hum Psychopharmacol 2008 23 1 1 11 18058852
  67. [79]Guerdjikova AI McElroy SL Winstanley EL Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial Int J Eat Disord 2012 45 2 281 289 21744377
  68. [80]Hudson JI McElroy SL Raymond NC Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial Am J Psychiatry 1998 155 12 1756 1762 9842788
  69. [81]Laederach-Hofmann K Graf C Horber F Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: a randomized, placebo-controlled double-blind study Int J Eat Disord 1999 26 3 231 244 10441239
  70. [82]McElroy SL Casuto LS Nelson EB Placebo-controlled trial of sertraline in the treatment of binge eating disorder Am J Psychiatry 2000 157 6 1004 1006 10831483
  71. [83]McElroy SL Arnold LM Shapira NA Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial Am J Psychiatry 2003 160 2 255 261 12562571
  72. [84]Pearlstein T Spurell E Hohlstein LA A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response Arch Womens Ment Health 2003 6 2 147 151 12720065
  73. [85]McCann UD Agras WS Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled study Am J Psychiatry 1990 147 11 1509 1513 2221164
  74. [86]Devlin MJ Goldfein JA Petkova E Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder Obes Res 2005 13 6 1077 1088 15976151
  75. [87]Grilo CM Masheb RM Salant SL Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial Biol Psychiatry 2005 57 10 1193 1201 15866560
  76. [89]Stefano SC Bacaltchuk J Blay SL Appolinario JC Antidepressants in short-term treatment of binge eating disorder: systematic review and meta-analysis Eat Behav 2008 9 2 129 136 18329590
  77. [90]Grilo CM Masheb RM Crosby RD Predictors and moderators of response to cognitive behavioral therapy and medication for the treatment of binge eating disorder J Consult Clin Psychol 1 30 2012 [Epub ahead of print.] PMC3342441 22289130
  78. [91]Fichter MM Kruger R Rief W Holland R Dohne J Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology J Clin Psychopharmacol 1996 16 1 9 18 8834413
  79. [92]Romano SJ Halmi KA Sarkar NP Koke SC Lee JS A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment Am J Psychiatry 2002 159 1 96 102 11772696
  80. [93]Leombruni P Piero A Brustolin A A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters Hum Psychopharmacol 2006 21 3 181 188 16625525
  81. [94]Leombruni P Piero A Lavagnino L Brustolin A Campisi S Fassino S A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with binge eating disorder Prog Neuropsychopharmacol Biol Psychiatry 2008 32 6 1599 1605 18598735
  82. [95]Devlin MJ Goldfein JA Petkova E Liu L Walsh BT Cognitive behavioral therapy and fluoxetine for binge eating disorder: two-year follow-up Obesity (Silver Spring) 2007 15 7 1702 1709 17636088
  83. [96]Calandra C Russo RG Luca M Bupropion versus sertraline in the treatment of depressive patients with binge eating disorder: retrospective cohort study Psychiatr Q 9 17 2011 [Epub ahead of print.] 21927936
  84. [97]Malhotra S King KH Welge JA Brusman-Lovins L McElroy SL Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients J Clin Psychiatry 2002 63 9 802 806 12363121
  85. [98]Bailer UF Bloss CS Frank GK 5-HT1A receptor binding is increased after recovery from bulimia nervosa compared with control women and is associated with behavioral inhibition in both groups Int J Eat Disord 2011 44 6 477 487 20872754 PMC4286242
  86. [99]Garattini S Biological actions of drugs affecting serotonin and eating Obes Res 1995 3 Suppl 4 463S 470S 8697044
  87. [100]Colman E Anorectics on trial: a half century of federal regulation of prescription appetite suppressants Ann Intern Med 2005 143 5 380 385 16144896
  88. [101]Gardin JM Schumacher D Constantine G Davis KD Leung C Reid CL Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine JAMA 2000 283 13 1703 1709 10755496
  89. [102]Stunkard A Berkowitz R Tanrikut C Reiss E Young L D-fenfluramine treatment of binge eating disorder Am J Psychiatry 1996 153 11 1455 1459 8890680
  90. [103]Padwal RS Majumdar SR Drug treatments for obesity: orlistat, sibutramine, and rimonabant Lancet 2007 369 9555 71 77 17208644
  91. [105]Appolinario JC Bacaltchuk J Sichieri R A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder Arch Gen Psychiatry 2003 60 11 1109 1116 14609886
  92. [106]Milano W Petrella C Casella A Capasso A Carrino S Milano L Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: A placebo-controlled study Adv Ther 2005 22 1 25 31 15943219
  93. [107]Franzoi SL Shields SA The Body Esteem Scale: multidimensional structure and sex differences in a college population J Pers Assess 1984 48 2 173 178 6726603
  94. [108]Golay A Laurent-Jaccard A Habicht F Effect of orlistat in obese patients with binge eating disorder Obes Res 2005 13 10 1701 1708 16286517
  95. [109]Fernandez-Aranda F Amor A Jimenez-Murcia S Gimenez-Martinez L Turon-Gil V Vallejo-Ruiloba J Bulimia nervosa and misuse of orlistat: two case reports Int J Eat Disord 2001 30 4 458 461 11746308
  96. [110]Hagler Robinson A Orlistat misuse as purging in a patient with binge-eating disorder Psychosomatics 2009 50 2 177 178 19377029
  97. [111]Rothman RB Baumann MH Dersch CM Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin Synapse 2001 39 1 32 41 11071707
  98. [112]Aronne LJ Halseth AE Burns CM Miller S Shen LZ Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial Obesity (Silver Spring) 2010 18 9 1739 1746 20094043
  99. [113]Ioannides-Demos LL Piccenna L McNeil JJ Pharmacotherapies for obesity: Past, current, and future therapies J Obes 2011 2011 179674 21197148 PMC3006492
  100. [114]Alger SA Malone M Cerulli J Fein S Howard L Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters Obes Res 1999 7 5 469 476 10509604
  101. [115]Devlin MJ Goldfein JA Carino JS Wolk SL Open treatment of overweight binge eaters with phentermine and fluoxetine as an adjunct to cognitive-behavioral therapy Int J Eat Disord 2000 28 3 325 332 10942919
  102. [116]Green RS Rau JH Treatment of compulsive eating disturbances with anticonvulsant medication Am J Psychiatry 1974 131 4 428 432 4814912
  103. [117]Hudson JI Pope HG Jr The role of anticonvulsants in the treatment of bulimia McElroy SL Pope HG Jr Use of Anticonvulsants in Psychiatry Clifton, NJ Oxford Health Care 1988
  104. [118]Rau JH Struve FA Green RS Electroencephalographic correlates of compulsive eating Clin Electroencephalogr 1979 10 4 180 189 498547
  105. [119]Moore SL Rakes SM Binge eating – therapeutic response to diphenylhydantoin: case report J Clin Psychiatry 1982 43 9 385 386 6956568
  106. [121]Gadde KM Franciscy DM Wagner HR 2nd Krishnan KR Zonisamide for weight loss in obese adults: a randomized controlled trial JAMA 2003 289 14 1820 1825 12684361
  107. [123]Olive MF Cleva RM Kalivas PW Malcolm RJ Glutamatergic medications for the treatment of drug and behavioral addictions Pharmacol Biochem Behav 2012 100 4 801 810 21536062 PMC3154511
  108. [125]Bray GA Hollander P Klein S A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity Obes Res 2003 11 6 722 733 12805393
  109. [127]Tonstad S Tykarski A Weissgarten J Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension Am J Cardiol 2005 96 2 243 251 16018851
  110. [128]Allison DB Gadde KM Garvey WT Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP) Obesity (Silver Spring) 2011 20 2 330 342 22051941 PMC3270297
  111. [129]Gadde KM Allison DB Ryan DH Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial Lancet 2011 377 9774 1341 1352 21481449
  112. [130]Garvey WT Ryan DH Look M Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study Am J Clin Nutr 2012 95 2 297 308 22158731 PMC3260065
  113. [131]Barratt ES Stanford MS Impulsiveness Cooper GC Impulsiveness in Personality Characteristics of the Personality Disordered Client New York, NY Wiley 1995
  114. [132]Claudino AM de Oliveira IR Appolinario JC Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder J Clin Psychiatry 2007 68 9 1324 1332 17915969
  115. [133]McElroy SL Shapira NA Arnold LM Topiramate in the long-term treatment of binge-eating disorder associated with obesity J Clin Psychiatry 2004 65 11 1463 1469 15554757
  116. [134]De Bernardi C Ferraris S D’Innella P Do F Torre E Topiramate for binge eating disorder Prog Neuropsychopharmacol Biol Psychiatry 2005 29 2 339 341 15694244
  117. [135]Dolberg OT Barkai G Gross Y Schreiber S Differential effects of topiramate in patients with traumatic brain injury and obesity – a case series Psychopharmacology (Berl) 2005 179 4 838 845 15619108
  118. [136]Kotwal R Guerdjikova A McElroy SL Keck PE Jr Lithium augmentation of topiramate for bipolar disorder with comorbid binge eating disorder and obesity Hum Psychopharmacol 2006 21 7 425 431 16941522
  119. [137]Schmidt do Prado-Lima PA Bacaltchuck J Topiramate in treatment-resistant depression and binge-eating disorder Bipolar Disord 2002 4 4 271 273 12190717
  120. [138]Shapira NA Goldsmith TD McElroy SL Treatment of binge-eating disorder with topiramate: a clinical case series J Clin Psychiatry 2000 61 5 368 372 10847312
  121. [139]Guerdjikova AI Kotwal R McElroy SL Response of recurrent binge eating and weight gain to topiramate in patients with binge eating disorder after bariatric surgery Obes Surg 2005 15 2 273 277 15802073
  122. [140]Zilberstein B Pajecki D Garcia de Brito AC Gallafrio ST Eshkenazy R Andrade CG Topiramate after adjustable gastric banding in patients with binge eating and difficulty losing weight Obes Surg 2004 14 6 802 805 15318986
  123. [141]Colom F Vieta E Benabarre A Topiramate abuse in a bipolar patient with an eating disorder J Clin Psychiatry 2001 62 6 475 476 11465528
  124. [142]McElroy SL Kotwal R Guerdjikova AI Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial J Clin Psychiatry 2006 67 12 1897 1906 17194267
  125. [144]Gadde KM Yonish GM Foust MS Wagner HR Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study J Clin Psychiatry 2007 68 8 1226 1229 17854247
  126. [145]McElroy SL Kotwal R Hudson JI Nelson EB Keck PE Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial J Clin Psychiatry 2004 65 1 50 56 14744168
  127. [146]Guerdjikova AI McElroy SL Welge JA Nelson E Keck PE Hudson JI Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial Int Clin Psychopharmacol 2009 24 3 150 158 19357528
  128. [147]Merideth CH A single-center, double-blind, placebo-controlled evaluation of lamotrigine in the treatment of obesity in adults J Clin Psychiatry 2006 67 2 258 262 16566621
  129. [149]Wermuth BM Davis KL Hollister LE Stunkard AJ Phenytoin treatment of the binge-eating syndrome Am J Psychiatry 1977 134 11 1249 1253 333952
  130. [150]Leombruni P Gastaldi F Lavagnino L Fassino S Oxcarbazepine for the treatment of binge eating disorder: a case series Adv Ther 2008 25 7 718 724 18636233
  131. [151]Bello NT Hajnal A Acute methylphenidate treatments reduce sucrose intake in restricted-fed bingeing rats Brain Res Bull 2006 70 4–6 422 429 17027778
  132. [152]Ong YL Checkley SA Russell GF Suppression of bulimic symptoms with methylamphetamine Br J Psychiatry 1983 143 288 293 6354341
  133. [153]Drimmer EJ Stimulant treatment of bulimia nervosa with and without attention-deficit disorder: three case reports Nutrition 2003 19 1 76 77 12507648
  134. [154]Dukarm CP Bulimia nervosa and attention deficit hyperactivity disorder: a possible role for stimulant medication J Womens Health (Larchmt) 2005 14 4 345 350 15916509
  135. [155]Schweickert LA Strober M Moskowitz A Efficacy of methylphenidate in bulimia nervosa comorbid with attention-deficit hyperactivity disorder: a case report Int J Eat Disord 1997 21 3 299 301 9097204
  136. [156]Sokol MS Gray NS Goldstein A Kaye WH Methylphenidate treatment for bulimia nervosa associated with a cluster B personality disorder Int J Eat Disord 1999 25 2 233 237 10065402
  137. [157]Silveira RO Zanatto V Appolinario JC Kapczinski F An open trial of reboxetine in obese patients with binge eating disorder Eat Weight Disord 2005 10 4 e93 e96 16682868
  138. [159]O’Brien CP Anticraving agents for the treatment of addictive disorders Curr Psychiatry Rep 2004 6 5 321 322 15355753
  139. [160]Gearhardt AN Yokum S Orr PT Stice E Corbin WR Brownell KD Neural correlates of food addiction Arch Gen Psychiatry 2011 68 8 808 816 21464344 PMC3980851
  140. [161]Gearhardt AN White MA Potenza MN Binge eating disorder and food addiction Curr Drug Abuse Rev 2011 4 3 201 207 21999695 PMC3671377
  141. [162]McElroy SL Guerdjikova AI Winstanley EL Acamprosate in the treatment of binge eating disorder: A placebo-controlled trial Int J Eat Disord 2011 44 1 81 90 21080416
  142. [163]Mitchell JE Christenson G Jennings J A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in out-patients with normal weight bulimia J Clin Psychopharmacol 1989 9 2 94 97 2656781
  143. [164]Marrazzi MA Bacon JP Kinzie J Luby ED Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa Int Clin Psychopharmacol 1995 10 3 163 172 8675969
  144. [165]Jonas JM Gold MS The use of opiate antagonists in treating bulimia: a study of low-dose versus high-dose naltrexone Psychiatry Res 1988 24 2 195 199 2841709
  145. [166]Raingeard I Courtet P Renard E Bringer J Naltrexone improves blood glucose control in type 1 diabetic women with severe and chronic eating disorders Diabetes Care 2004 27 3 847 848 14988322
  146. [167]Drewnowski A Krahn DD Demitrack MA Nairn K Gosnell BA Naloxone, an opiate blocker, reduces the consumption of sweet high-fat foods in obese and lean female binge eaters Am J Clin Nutr 1995 61 6 1206 1212 7762518
  147. [169]Greenway FL Fujioka K Plodkowski RA Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet 2010 376 9741 595 605 20673995
  148. [170]Wadden TA Foreyt JP Foster GD Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial Obesity (Silver Spring) 2011 19 1 110 120 20559296 PMC4459776
  149. [171]Marrazzi MA Markham KM Kinzie J Luby ED Binge eating disorder: response to naltrexone Int J Obes Relat Metab Disord 1995 19 2 143 145 7735342
  150. [172]Meyer F Alleviation of both binge eating and sexual dysfunction with naltrexone J Clin Psychopharmacol 2008 28 6 722 723 19011456
  151. [173]Neumeister A Winkler A Wober-Bingol C Addition of naltrexone to fluoxetine in the treatment of binge eating disorder Am J Psychiatry 1999 156 5 797 10327921
  152. [174]Hillemacher T Heberlein A Muschler MA Bleich S Frieling H Opioid modulators for alcohol dependence Expert Opin Investig Drugs 2011 20 8 1073 1086 21651459
  153. [176]Blednov YA Adron Harris R Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions Int J Neuropsychopharmacol 2008 11 6 775 793 18377703 PMC2574715
  154. [177]Hermanussen M Tresguerres JA A new anti-obesity drug treatment: first clinical evidence that antagonising glutamate-gated Ca2+ ion channels with memantine normalises binge-eating disorders Econ Hum Biol 2005 3 2 329 337 15886075
  155. [178]Brennan BP Roberts JL Fogarty KV Reynolds KA Jonas JM Hudson JI Memantine in the treatment of binge eating disorder: an open-label, prospective trial Int J Eat Disord 2008 41 6 520 526 18433015
  156. [179]Zaharna M Dimitriu A Guilleminault C Expert opinion on pharmacotherapy of narcolepsy Expert Opin Pharmacother 2010 11 10 1633 1645 20426704
  157. [180]Pardi D Black J Gamma-hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness CNS Drugs 2006 20 12 993 1018 17140279
  158. [181]Fortuyn HA Swinkels S Buitelaar J High prevalence of eating disorders in narcolepsy with cataplexy: a case-control study Sleep 2008 31 3 335 341 18363309 PMC2276738
  159. [182]McElroy SL Guerdjikova AI Winstanley EL Sodium oxybate in the treatment of binge eating disorder: an open-label, prospective study Int J Eat Disord 2011 44 3 262 268 20209489
  160. [183]Broft AI Spanos A Corwin RL Baclofen for binge eating: an open-label trial Int J Eat Disord 2007 40 8 687 691 17647277
  161. [184]Brewerton TD Shannon M Possible clozapine exacerbation of bulimia nervosa Am J Psychiatry 1992 149 10 1408 1409 1530082
  162. [185]Gebhardt S Haberhausen M Krieg JC Clozapine/olanzapine-induced recurrence or deterioration of binge eating-related eating disorders J Neural Transm 2007 114 8 1091 1095 17372672
  163. [186]Theisen FM Linden A Konig IR Martin M Remschmidt H Hebebrand J Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine J Neural Transm 2003 110 1 111 121 12541016
  164. [187]Jacobs-Pilipski MJ Wilfley DE Crow SJ Placebo response in binge eating disorder Int J Eat Disord 2007 40 3 204 211 17103417 PMC2798075
  165. [188]Guerdjikova AI McElroy SL Binge eating disorder pharmacotherapy clinical trials – who is left out? Eur Eat Disord Rev 2009 17 2 101 108 18683898
  166. [189]Berlim MT Fleck MP Turecki G Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview Ann Med 2008 40 2 149 159 18293145
  167. [190]Brambilla F Samek L Company M Lovo F Cioni L Mellado C Multivariate therapeutic approach to binge-eating disorder: Combined nutritional, psychological and pharmacological treatment Int Clin Psychopharmacol 2009 24 6 312 317 19794312
  168. [191]Zarate CA Manji HK Riluzole in psychiatry: a systematic review of the literature Expert Opin Drug Metab Toxicol 2008 4 9 1223 1234 18721116 PMC2587133
  169. [192]Fidler MC Sanchez M Raether B A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial J Clin Endocrinol Metab 2011 96 10 3067 3077 21795446
  170. [193]Astrup A Madsbad S Breum L Jensen TJ Kroustrup JP Larsen TM Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial Lancet 2008 372 9653 1906 1913 18950853
  171. [194]Field BC Wren AM Cooke D Bloom SR Gut hormones as potential new targets for appetite regulation and the treatment of obesity Drugs 2008 68 2 147 163 18197723
  172. [195]Heal DJ Smith SL Fisas A Codony X Buschmann H Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders Pharmacol Ther 2008 117 2 207 231 18068807
  173. [196]Rivera G Bocanegra-Garcia V Galiano S Melanin- concentrating hormone receptor 1 antagonists: a new perspective for the pharmacologic treatment of obesity Curr Med Chem 2008 15 10 1025 1043 18393860
  174. [197]Smith SR Prosser WA Donahue DJ Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women Obesity (Silver Spring) 2009 17 3 494 503 19057523
  175. [198]Smith SR Weissman NJ Anderson CM Multicenter, placebo-controlled trial of lorcaserin for weight management N Engl J Med 2010 363 3 245 256 20647200
  176. [199]Tran P Skolnick P Czobor P Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial J Psychiatr Res 2012 46 1 64 71 21925682
  177. [200]Sysko R Hildebrandt T Wilson GT Wilfley DE Agras WS Heterogeneity moderates treatment response among patients with binge eating disorder J Consult Clin Psychol 2010 78 5 681 690 20873903 PMC2948417
  178. [201]Bulik CM Hebebrand J Keski-Rahkonen A Genetic epidemiology, endophenotypes, and eating disorder classification Int J Eat Disord 2007 40 Suppl S52 60 17573683

Authors
McElroy, S., Guerdjikova, A. I., Mori, N., & O’Melia, A.
Affiliations
Lindner Center of HOPE (US)
Corresponding author
  • Guerdjikova, Anna I.
  • Mori, Nicole
  • O’Melia, Anne
ORCID
Venue
Therapeutics and Clinical Risk Management
Publisher
Informa UK Limited
Published
2012-05
Volume
8
Pages
219
ISSN
  • 1176-6336 (ISSN-L)
  • 1178-203X
DOI
10.2147/tcrm.s25574
PMC
PMC3363296
OpenAlex
W2027342753
Cited by
74
References
205
Citations by year
2026: 4 · 2025: 3 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 4 · 2020: 5 · 2019: 6 · 2018: 6 · 2017: 6 · 2016: 9 · 2015: 12 · 2014: 7 · 2013: 5 · 2012: 2
FWCI
9.46
Type
journal article
Language
en
Open access
Licence
Locations
  • Therapeutics and Clinical Risk Management (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
  • Abbott Laboratories
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • University of Cincinnati
  • Jazz Pharmaceuticals
  • Orexigen Therapeutics
  • J. Willard and Alice S. Marriott Foundation
  • Agency for Healthcare Research and Quality
  • National Institute of Mental Health
Topics
  • Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Nursing › Nutrition and Dietetics › Nutrition, Health and Food Behavior
Keywords
binge eating disorder, pharmacotherapy, antidepressants, anorectic drugs, appetite suppressants, treatment options, eating disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review